drugset / Trial / NCT02478164

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

NCT02478164 ↗

Phase 2 Completed 17 enrolled Dana-Farber Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.

Timeline

Start
2015-07-13
Primary completion
2017-07-08
Completion
2018-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponatinib Small molecule — Oral

Indications